Japan’s Meiji Seika To Enlarge Generics Production Capacity In Thailand
This article was originally published in PharmAsia News
Executive Summary
Japanese generic-drug maker Meiji Seika Kaisha plans to invest heavily in production in Thailand by the end of next year. The company, which currently markets 33 generics, 80 percent of which belong to other companies, plans to produce its own generics of some of the best-selling medicines. Plans call for investing $1.9 million to improve production lines of its Thai subsidiary, Thai Meiji Pharmaceutical, to increase capacity from the current 4 million tablets a year to 70 million. (Click here for more - a subscription may be required